{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:17:13Z","timestamp":1790813833623,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.conb.2019.11.019","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T20:25:00Z","timestamp":1576182300000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead"],"prefix":"10.1016","volume":"61","author":[{"given":"Joel","family":"Simr\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2019.11.019_bib0005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.conb.2019.11.019_bib0010","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/aww224","article-title":"TDP-43 stage, mixed pathologies, and clinical Alzheimer\u2019s-type dementia","volume":"139","author":"James","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.conb.2019.11.019_bib0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0020","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0030","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/brain\/awz099","article-title":"Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report","volume":"142","author":"Nelson","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.conb.2019.11.019_bib0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.conb.2019.11.019_bib0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2217\/bmm-2017-0433","article-title":"Update on biomarkers for amyloid pathology in Alzheimer\u2019s disease","volume":"12","author":"Ashton","year":"2018","journal-title":"Biomark Med"},{"key":"10.1016\/j.conb.2019.11.019_sbref0045","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","author":"McDade","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_sbref0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13195-019-0517-9","article-title":"Towards a unified protocol for handling of CSF before beta-amyloid measurements","volume":"11","author":"Janelidze","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.conb.2019.11.019_bib0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.conb.2019.11.019_bib0065","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.2214","article-title":"Staging beta-amyloid pathology with amyloid positron emission tomography","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/JAD-160322","article-title":"Cerebrospinal fluid Alzheimer\u2019s disease biomarkers across the spectrum of lewy body diseases: results from a large multicenter cohort","volume":"54","author":"van Steenoven","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.conb.2019.11.019_bib0080","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jalz.2014.12.006","article-title":"CSF biomarkers for the differential diagnosis of Alzheimer\u2019s disease: a large-scale international multicenter study","volume":"11","author":"Ewers","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0085","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0090","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.conb.2019.11.019_sbref0095","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_bib0100","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2019.11.019_sbref0105","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0110","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.dadm.2019.05.007","article-title":"Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition","volume":"11","author":"Risacher","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.conb.2019.11.019_bib0115","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-beta (Abeta42) Correlates with cerebrospinal fluid Abeta42 in Alzheimer\u2019s disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.conb.2019.11.019_bib0120","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00175","article-title":"The relation between brain amyloid deposition, cortical atrophy, and plasma biomarkers in amnesic mild cognitive impairment and Alzheimer\u2019s disease","volume":"10","author":"Fan","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.conb.2019.11.019_sbref0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0361-9230(03)00086-8","article-title":"CSF markers for pathogenic processes in Alzheimer\u2019s disease: diagnostic implications and use in clinical neurochemistry","volume":"61","author":"Blennow","year":"2003","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.conb.2019.11.019_bib0135","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","article-title":"Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation","volume":"91","author":"Citron","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2019.11.019_sbref0140","doi-asserted-by":"crossref","first-page":"eaav1388","DOI":"10.1126\/sciadv.aav1388","article-title":"Comparative analyses of plasma amyloid-beta levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system","volume":"5","author":"Kim","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.conb.2019.11.019_sbref0145","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41467-019-09030-2","article-title":"Subtyping of circulating exosome-bound amyloid beta reflects brain plaque deposition","volume":"10","author":"Lim","year":"2019","journal-title":"Nat Commun"},{"issue":"Suppl. 1","key":"10.1016\/j.conb.2019.11.019_bib0150","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.parkreldis.2015.09.020","article-title":"Tauopathies as clinicopathological entities","volume":"22","author":"Irwin","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.conb.2019.11.019_bib0155","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","article-title":"Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish mortality registry","volume":"71","author":"Skillback","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0160","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s007020070079","article-title":"CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging","volume":"107","author":"Sjogren","year":"2000","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.conb.2019.11.019_bib0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","article-title":"Biomarkers for tau pathology","volume":"97","author":"Scholl","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.conb.2019.11.019_sbref0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2019.11.019_bib0175","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1007\/s00259-018-4242-6","article-title":"Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer\u2019s disease","volume":"46","author":"Leuzy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.conb.2019.11.019_sbref0180","doi-asserted-by":"crossref","first-page":"e11170","DOI":"10.15252\/emmm.201911170","article-title":"Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease","author":"Palmqvist","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.conb.2019.11.019_sbref0185","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuron.2018.04.035","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"98","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.conb.2019.11.019_bib0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.resuscitation.2012.07.027","article-title":"Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study","volume":"84","author":"Randall","year":"2013","journal-title":"Resuscitation"},{"key":"10.1016\/j.conb.2019.11.019_bib0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurobiolaging.2017.06.002","article-title":"Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease","volume":"58","author":"Pereira","year":"2017","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.conb.2019.11.019_bib0200","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","article-title":"Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort","volume":"12","author":"Dage","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0205","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_bib0210","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0215","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","article-title":"Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes","volume":"76","author":"Pase","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0220","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3233\/JAD-161114","article-title":"Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer\u2019s disease","volume":"58","author":"Deters","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.conb.2019.11.019_bib0225","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/jnnp-2017-317260","article-title":"Plasma tau is increased in frontotemporal dementia","volume":"89","author":"Foiani","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_bib0230","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1038\/s41598-017-09009-3","article-title":"Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases","volume":"7","author":"Yang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2019.11.019_bib0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1071","article-title":"Association of blood and cerebrospinal fluid Tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease","author":"Staffaroni","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0240","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jnnp-2017-317793","article-title":"Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression","volume":"89","author":"Thompson","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_bib0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","article-title":"Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease","volume":"15","author":"Chen","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","article-title":"Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome","volume":"12","author":"Tatebe","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.conb.2019.11.019_bib0255","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3233\/JAD-170810","article-title":"Assay of plasma phosphorylated tau protein (Threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease","volume":"61","author":"Yang","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.conb.2019.11.019_sbref0260","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1212\/WNL.56.1.127","article-title":"Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease","volume":"56","author":"Masliah","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_bib0270","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF01273157","article-title":"Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele","volume":"103","author":"Blennow","year":"1996","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.conb.2019.11.019_bib0275","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","article-title":"Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls","volume":"7","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.conb.2019.11.019_sbref0285","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00401-018-1851-x","article-title":"Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology","volume":"136","author":"Portelius","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2019.11.019_bib0290","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0295","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","article-title":"Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease","volume":"73","author":"Tarawneh","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0300","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/jnnp-2018-320155","article-title":"CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD","volume":"90","author":"Blennow","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_bib0305","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0407-6","article-title":"Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer\u2019s disease","volume":"10","author":"Zhang","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.conb.2019.11.019_bib0310","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","article-title":"The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer\u2019s disease","volume":"8","author":"Ohrfelt","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.conb.2019.11.019_sbref0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2018.08.006","article-title":"Elevated CSF GAP-43 is Alzheimer\u2019s disease specific and associated with tau and amyloid pathology","volume":"15","author":"Sandelius","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0320","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12883-018-1210-5","article-title":"Transient increase in CSF GAP-43 concentration after ischemic stroke","volume":"18","author":"Sandelius","year":"2018","journal-title":"BMC Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0325","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.23798","article-title":"NPTX2 and cognitive dysfunction in Alzheimer\u2019s disease","volume":"6","author":"Xiao","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.conb.2019.11.019_bib0330","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer\u2019s disease","volume":"11","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_bib0335","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1096\/fj.201600816R","article-title":"Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease","volume":"30","author":"Goetzl","year":"2016","journal-title":"FASEB J"},{"key":"10.1016\/j.conb.2019.11.019_bib0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dadm.2016.04.001","article-title":"Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile","volume":"3","author":"Winston","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.conb.2019.11.019_sbref0345","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson\u2019s disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0350","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.conb.2019.11.019_bib0355","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","article-title":"REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease","volume":"91","author":"Pagano","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_bib0360","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_bib0365","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","article-title":"Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression","volume":"31","author":"Majbour","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2019.11.019_bib0370","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_sbref0375","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00415","article-title":"Are we ready for detecting alpha-synuclein prone to aggregation in patients? The case of \"protein-misfolding cyclic amplification\" and \"real-time quaking-induced conversion\" as diagnostic tools","volume":"9","author":"Paciotti","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0385","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.conb.2019.11.019_bib0390","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease","volume":"68","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_sbref0395","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0400","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-019-1399-2","article-title":"Glial activation and inflammation along the Alzheimer\u2019s disease continuum","volume":"16","author":"Nordengen","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.conb.2019.11.019_bib0405","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","article-title":"CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.conb.2019.11.019_sbref0410","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","article-title":"Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease","volume":"15","author":"Schindler","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.conb.2019.11.019_sbref0415","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","article-title":"Plasma YKL-40 in the spectrum of neurodegenerative dementia","volume":"16","author":"Villar-Pique","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.conb.2019.11.019_bib0420","doi-asserted-by":"crossref","first-page":"13276","DOI":"10.1038\/s41598-018-31517-z","article-title":"Cerebrospinal fluid concentrations of inflammatory markers in Parkinson\u2019s disease and atypical parkinsonian disorders","volume":"8","author":"Hall","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2019.11.019_bib0425","doi-asserted-by":"crossref","first-page":"466","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers","volume":"8","author":"Suarez-Calvet","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.conb.2019.11.019_bib0430","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","article-title":"Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status","volume":"131","author":"Piccio","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","article-title":"Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology","volume":"14","author":"Suarez-Calvet","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.conb.2019.11.019_bib0440","doi-asserted-by":"crossref","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","article-title":"Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury","volume":"8","author":"Suarez-Calvet","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.conb.2019.11.019_bib0445","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1177\/1352458515624558","article-title":"Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone","volume":"22","author":"Ohrfelt","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.conb.2019.11.019_bib0450","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00415-011-6087-9","article-title":"Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer\u2019s disease","volume":"258","author":"Choi","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0455","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41598-018-19807-y","article-title":"Plasma MCP-1 and cognitive decline in patients with Alzheimer\u2019s disease and mild cognitive impairment: a two-year follow-up study","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2019.11.019_bib0460","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1093\/brain\/awn217","article-title":"Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation","volume":"131","author":"Piccio","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.conb.2019.11.019_bib0465","doi-asserted-by":"crossref","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","article-title":"TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis","volume":"6","author":"Kleinberger","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.conb.2019.11.019_bib0470","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-130854","article-title":"Increased expression of TREM2 in peripheral blood of Alzheimer\u2019s disease patients","volume":"38","author":"Hu","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.conb.2019.11.019_bib0475","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.conb.2019.11.019_bib0480","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1001\/archneur.65.11.1481","article-title":"TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"65","author":"Steinacker","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0485","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00401-009-0594-0","article-title":"Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration","volume":"118","author":"Foulds","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2019.11.019_bib0490","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp-2013-305972","article-title":"Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation","volume":"85","author":"Suarez-Calvet","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_bib0495","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","article-title":"TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"116","author":"Foulds","year":"2008","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.conb.2019.11.019_bib0500","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","article-title":"Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion","volume":"17","author":"Atarashi","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2019.11.019_bib0505","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamaneurol.2016.4614","article-title":"Diagnosis of human prion disease using real-time quaking-induced conversion testing of olfactory mucosa and cerebrospinal fluid samples","volume":"74","author":"Bongianni","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0510","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/978-1-4939-7244-9_21","article-title":"Real-time quaking-induced conversion for diagnosis of prion disease","volume":"1658","author":"Satoh","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.conb.2019.11.019_sbref0515","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/practneurol-2018-001935","article-title":"RT-QuIC: a new test for sporadic CJD","volume":"19","author":"Green","year":"2019","journal-title":"Pract Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0520","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ana.24833","article-title":"Diagnostic and prognostic value of human prion detection in cerebrospinal fluid","volume":"81","author":"Foutz","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0525","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.conb.2019.11.019_sbref0530","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-018-0127-7","article-title":"Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer\u2019s disease","volume":"7","author":"Zhang","year":"2018","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.conb.2019.11.019_bib0535","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.22448","article-title":"Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease","volume":"70","author":"Tarawneh","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.conb.2019.11.019_bib0540","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3233\/JAD-150705","article-title":"Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer\u2019s disease early detection and differential diagnosis in patients with mild cognitive impairment","volume":"50","author":"Babic Leko","year":"2016","journal-title":"J Alzheimers Dis"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438819301308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438819301308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:52:59Z","timestamp":1760705579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438819301308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":108,"alternative-id":["S0959438819301308"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2019.11.019","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2019.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}